ClinicalTrials.gg
TerminatedNCT04985136Updated Sep 1, 2022

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

A Phase 3 interventional study of camrelizumab;Rivoceranib and Rivoceranib in Advanced Hepatocellular Carcinoma (HCC), sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor R \& D Strategy Adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Hepatocellular · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
13th of 13
1 · median 251
Started
2021
with 1 other
Phase 3
7 of 13
2 open now
Registered
6th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., this one is the 13th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, and was the 6th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of Patients with Hepatocellular Carcinoma (HCC)

03

Conditions studied

  • Advanced Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must participate voluntarily and sign the form;
  2. Aged ≥ 18 years old, male or female;
  3. Histopathologically confirmed hepatocellular carcinoma;
  4. Has PD on treatment with prior /PD-L1/CTLA-4 monoclonal antibody (mAb) administered either as monotherapy or as combination therapy.
  5. No more than 2 lines of previous system treatment;
  6. Be able to provide fresh or archived tumor tissue samples;
  7. Patient with at least one (for Stage I);
  8. Barcelona clinic liver cancer: Stage B or C;
  9. score: ≤ 7;
  10. PS score of 0-1;
  11. of ≥ 12 weeks;
  12. Adequate organ function
  13. Must take one medically approved measure

Exclusion criteria

Exclusion Criteria:

  1. Patients with any active, known or suspected disorder;
  2. Patients who have used or other agents for systemic treatment within 1 month prior to randomization;
  3. With known severe allergic reactions to any other monoclonal antibodies;
  4. Received previous camrelizumab or rivoceranib mesylate treatment;
  5. Patients who discontinued ICIs treatment due to immune-related toxicity;
  6. Patients with known or hepatic encephalopathy;
  7. Patients with liver tumor burden greater than 50% of total liver in volume, or patients who have previously undergone liver transplantation;;
  8. Patients with symptomatic ascites or pleural effusion requiring paracentesis and drainage, or patients who have undergone ascites or pleural effusion drainage within 2 weeks before randomization;
  9. Patients with other currently or within the past 5 years;
  10. Patients with hypertension which cannot be well controlled by antihypertensives; history of hypertensive crisis or hypertensive encephalopathy;
  11. Uncontrolled cardiac diseases or symptoms;
  12. Known hereditary or acquired bleeding disorders;
  13. bleeding symptoms or clear bleeding tendency;
  14. Patients with gastrointestinal perforation or gastrointestinal fistula;
  15. Patients with significant vascular invasions with a high possibility of fatal bleeding;
  16. Patients with important arterial/venous thrombosis;
  17. Patients experiencing toxicity caused by previous anti-tumor therapy that has not recovered to Grade ≤ 1;
  18. Patients with active infection;
  19. Patients with congenital or acquired immune deficiency;
  20. Patients who received within 28 days prior to randomization, or are expect to be vaccinated during the treatment period;
  21. Patients with other potential factors that may affect the study results.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    camrelizumab + Rivoceranib

    Drug: camrelizumab;Rivoceranib

  • Active comparator
    Rivoceranib

    Drug: Rivoceranib

  • Active comparator
    Sorafenib

    Drug: Sorafenib

  • Active comparator
    Regorafenib

    Drug: Regorafenib

Interventions

  • Drugcamrelizumab;Rivoceranib

    Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)

  • Rivoceranib mesylate (750 mg, QD, po)

  • Sorafenib tosylate (400 mg, twice a day (BID), po)

  • Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)

06

What researchers measure

Primary outcomes

  1. Stage I:Objective Response Rate(ORR)

    Time frame: 2.5 years

  2. Stage II:Overall survival (OS)

    Time frame: 2.5 years

Secondary outcomes

  1. Stage I:Overall survival (OS)

    Time frame: 2.5 years

  2. Adverse Events(AEs)

    Time frame: 2.5 years

  3. Stage II:Objective Response Rate(ORR)

    Time frame: 2.5 years

  4. Disease Control Rate(DCR)

    Time frame: 2.5 years

  5. Duration of Response(DoR)

    Time frame: 2.5 years

  6. Progression-Free-Survival (PFS)

    Time frame: 2.5 years

  7. time to progression (TTP)

    Time frame: 2.5 years

  8. Pharmacokinetics (PK) Ctrough of camrelizumab

    Time frame: 2.5 years

  9. Pharmacokinetics (PK) Ctrough of Apatinib

    Time frame: 2.5 years

  10. Proportion of anti- camrelizumab antibody (ADA)

    Time frame: 2.5 years

  11. Proportion of neutralizing antibody (Nab)

    Time frame: 2.5 years

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Aug 2, 2021
StartActual
Sep 26, 2021
Primary completionActual
Dec 29, 2021
CompletionActual
Dec 29, 2021
Last update
Sep 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04985136
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Sep 26, 2021
Primary completion
Dec 29, 2021
Completion
Dec 29, 2021
Last update
Sep 1, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion